Pemetrexed MarketPemetrexed Market Size Will Escalate Rapidly in the Near Future

Pemetrexed Market Size,
Outlook, Future Growth
Synthesis 2018 - 2026
Share, Trend,
Analysis And
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small
cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name
Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as
an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination
with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic
NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance
therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/
2458
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of
pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast
period.
For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched
Pemetrexed STADA generic version of Alimta in Europe. High prevalence of non-small cell lung cancer
and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support
global pemetrexed market growth over the forecast period.
For instance, according to the data published by American Society of Clinical Oncology, in January
2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung
cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for
80% to 85% of all lung cancer diagnose.
North America is expected to Hold Dominant Position, Owing to High Prevalence of Non-small Cell Lung
Cancer and its High Treatment Rate in the U.S.
According to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed) generated around 50% of
its revenue from the U.S. Hence, North America is expected to be most conducive region for growth of
the pemetrexed market, due to high prevalence of non-small cell lung cancer and high cost for its
treatment.
For instance, according to the data published by the American Cancer Society in 2017, lung cancer (both
small cell and non-small cell) is the second most common type of cancer in U.S and around 13% of all
new cancers are lung cancer.
American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer
(116,440 in men and 111,710 in women) would be diagnosed in the U.S. and survival rate for
non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage IIIA
NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).
Report includes chapters which deeply display the following deliverable about industry :
• Pemetrexed Market Research Objective and Assumption
• Pemetrexed Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Pemetrexed Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Pemetrexed Market, By Regions
• Pemetrexed Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Pemetrexed Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Pemetrexed Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Pemetrexed Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada
Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.
Detailed Segmentation:
Global Pemetrexed Market, By Strength :
•
100 mg
•
500 mg
Global Pemetrexed Market, By Distribution Channel:
•
Hospital Pharmacies
•
Retail Pharmacies
•
Online Pharmacies
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/
pemetrexed-market-2458
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

The global pemetrexed market size was valued at US$ 2062.5 Mn in 2017 and is expected to witness a CAGR of 1.3% during the forecast period 2018 – 2026.